New hope: antiviral cocktail may block hepatitis b in newborns
NCT ID NCT04704024
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether giving antiviral medication to pregnant women with hepatitis B and their newborns can prevent the virus from passing to the baby. The study involves 450 women and their infants in Africa. The goal is to find a safe and effective way to reduce mother-to-child transmission of hepatitis B.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tenofovir disoproxil fumarate (TDF) and lamivudine (3TC)
- What this could lead to
- If successful, this could provide a safe and effective way to prevent hepatitis B infection in newborns in Africa, reducing the number of children who get the disease.
- What could go wrong
- This is a single trial with 450 participants, and results may not apply to all populations. There are also risks of side effects from the antiviral drugs, and the study is still ongoing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.